We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
-4.85%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$1.91M
Cap. Flow
+$19.3M
Cap. Flow %
9.17%
Top 10 Hldgs %
63.34%
Holding
39
New
3
Increased
22
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$8.5M
2
LLY icon
Eli Lilly
LLY
+$5.39M
3
BSX icon
Boston Scientific
BSX
+$4.23M
4
RVMD icon
Revolution Medicines
RVMD
+$3.14M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.44M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.39M
2
MRK icon
Merck
MRK
+$5.05M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$3.31M
4
IMCR icon
Immunocore
IMCR
+$1.68M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.05T
$28.7M 13.6%
37,068
+6,504
+21% +$5.39M
UNH icon
2
UnitedHealth
UNH
$367B
$17.9M 8.48%
35,202
-288
-0.8% -$164K
ABBV icon
3
AbbVie
ABBV
$430B
$16M 7.58%
90,723
+46,237
+104% +$8.5M
BSX icon
4
Boston Scientific
BSX
$72.5B
$13.8M 6.56%
154,222
+48,050
+45% +$4.23M
TMO icon
5
Thermo Fisher Scientific
TMO
$212B
$12.9M 6.13%
24,896
+2,884
+13% +$1.59M
MRK icon
6
Merck
MRK
$318B
$10.4M 4.93%
105,727
-48,972
-32% -$5.05M
SYK icon
7
Stryker
SYK
$129B
$9.3M 4.41%
25,660
+2,200
+9% +$815K
NBIX icon
8
Neurocrine Biosciences
NBIX
$16.4B
$9.29M 4.41%
67,763
+7,156
+12% +$885K
ALKS icon
9
Alkermes
ALKS
$8.19B
$7.67M 3.64%
266,499
+29,889
+13% +$859K
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$123B
$7.6M 3.6%
22,257
+5,264
+31% +$2.44M
COR icon
11
Cencora
COR
$60.9B
$7.31M 3.47%
32,553
-3,991
-11% -$939K
AMGN icon
12
Amgen
AMGN
$218B
$7.11M 3.37%
27,414
-1,551
-5% -$460K
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.94M 2.82%
71,138
-13,440
-16% -$1.1M
EW icon
14
Edwards Lifesciences
EW
$51.2B
$5.07M 2.4%
68,296
+31,791
+87% +$2.23M
MIRM icon
15
Mirum Pharmaceuticals
MIRM
$5.77B
$4.81M 2.28%
116,692
-21,629
-16% -$901K
DXCM icon
16
DexCom
DXCM
$31.3B
$4.68M 2.22%
60,057
+6,300
+12% +$466K
HRMY icon
17
Harmony Biosciences
HRMY
$2.24B
$4.1M 1.95%
120,501
-31,374
-21% -$1.08M
CAH icon
18
Cardinal Health
CAH
$54.9B
$3.62M 1.72%
30,680
+3,180
+12% +$371K
NAMS icon
19
NewAmsterdam Pharma
NAMS
$3.27B
$3.56M 1.69%
138,983
– –
ACLX
20
DELISTED
Arcellx
ACLX
$3.3M 1.56%
42,071
+1,841
+5% +$159K
UFPT icon
21
UFP Technologies
UFPT
$2.42B
$3.17M 1.5%
23,159
+5,111
+28% +$1.49M
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$3.08M 1.46%
326,840
+51,368
+19% +$534K
BBIO icon
23
BridgeBio Pharma
BBIO
$16.3B
$2.81M 1.34%
103,032
+49,600
+93% +$1.28M
RVMD icon
24
Revolution Medicines
RVMD
$42.2B
$2.68M 1.27%
+62,161
New +$3.14M
MRUS
25
DELISTED
Merus
MRUS
$2.62M 1.24%
62,521
+11,834
+23% +$568K
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q4 2024 Portfolio in Review

As of Q4 2024, HealthInvest Partners held 39 positions worth $211M, down 0.9% from $213M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

HealthInvest Partners deployed $19.3M of net new capital in Q4 2024, opening 3 new positions and adding to 22 existing holdings. Its largest new stake was Revolution Medicines: 62,161 shares worth $2.68M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merck, an estimated $5.05M trimmed.

  • HealthInvest Partners's largest Q4 2024 buy was Revolution Medicines: 62,161 shares worth $2.68M.
  • HealthInvest Partners added most to AbbVie in Q4 2024, an estimated $8.5M increase.
  • HealthInvest Partners's biggest Q4 2024 reduction was Merck, cutting an estimated $5.05M.
  • HealthInvest Partners fully exited Regeneron Pharmaceuticals in Q4 2024, selling an estimated $7.39M.
  • HealthInvest Partners's ten largest holdings make up 63% of its $211M portfolio in Q4 2024.
  • HealthInvest Partners opened 3 new positions and closed 3 in Q4 2024.
  • HealthInvest Partners's portfolio value fell 0.9% quarter-over-quarter to $211M.

Based on HealthInvest Partners's 13F filing for Q4 2024, filed 4 Feb 2025.